Related to Apeiron Licenses Phase II/III Anticancer Ab-IL2 Fusion Protein from Merck KGaA

• Cancer Research UK to Conduct Phase I Trial with Merck KGaA’s B-Cell Lymphoma Candidate
  
• Idera Receives $4.3M with Merck KGaA’s Initiation of a Phase II Head and Neck Cancer Trial
  
• GSK Pays Apeiron About $17.5M Up Front for Early Clinical-Stage ACE2 Candidate
  
• Lpath Bags $2M Asonep Milestone from Merck KGaA and then Severs Ties
  
• Apeiron Teams Up with Evotec for R&D in Pain
  
• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• Evotec and Merck KGaA Sign Neurological Drug Discovery Deal
  
• Merck KGaA and Sanofi-Aventis to Evaluate Combinations of Phase I Anticancer Compounds
  
• Alexion Pads Biologic R&D with $111M Acquisition of Taligen
  
• Apeiron Nabs Option to Cleveland Clinic’s Preclincial SHP-1 Inhibitors
  
• Human Genome Sciences Pays FivePrime $50M Up Front for Phase I Anticancer Agent
  
• Merck KGaA to Use MDxHealth’s Assay in Second Clinical Glioblastoma Study
  
• Zymeworks Secures $8.1M to Advance Antibody and Protein Therapeutics
  
• Merck KGaA Returns All Rights to Anticancer TLR9 Agonists to Idera
  
• Merck KGaA Nabs Threshold’s Late-Stage Hypoxia-Targeting Anticancer Drug for Initial $25M
  
• Threshold Pharma Gets $20M from Merck KGaA After Phase II Success with Anticancer Agent
  
• Dual-Antibody Anticancer Candidate Gets $25M Boost
  
• Apeiron Gains Rights to Phase III-Stage Neuroblastoma Treatment
  
• Apeiron Out-Licenses Antibody-Based Immunotherapy
  
• Children’s Oncology Group Joins Forces with Apeiron in Pediatric Neuroblastoma Trial